Q1 2020 13F Holders as of 31 Mar 2020
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
28,862,345
-
Total 13F shares
-
18,020,619
-
Share change
-
-421,860
-
Total reported value
-
$927,779,000
-
Put/Call ratio
-
127%
-
Price per share
-
$51.43
-
Number of holders
-
154
-
Value change
-
-$32,712,586
-
Number of buys
-
77
-
Number of sells
-
80
Institutional Holders of ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (ENTA) as of Q1 2020
As of 31 Mar 2020,
ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (ENTA) was held by
154 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
18,020,619 shares.
The largest 10 holders included
BlackRock Inc., FARALLON CAPITAL MANAGEMENT LLC, VANGUARD GROUP INC, PRICE T ROWE ASSOCIATES INC /MD/, STATE STREET CORP, RENAISSANCE TECHNOLOGIES LLC, DIMENSIONAL FUND ADVISORS LP, Krensavage Asset Management, LLC, ARMISTICE CAPITAL, LLC, and FIRST MANHATTAN CO.
This page lists
154
institutional shareholders reporting positions in this security
for the Q1 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.